Seeking Alpha
29 Jul 2026, 18:36 UTC · 2h ago
Coherus Oncology: The Catalyst Rich Period Is Here
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Seeking Alpha
29 Jul 2026, 18:36 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Coherus Oncology has multiple clinical readouts for tagmokitug and casdozokitug scheduled for H2'26 and H1'27. — Clinical trial results are primary binary catalysts for biotech valuations and can cause significant price swings.
+0.60Potential future capital raises are identified as a key risk for the company. — Equity offerings typically lead to share dilution, which is viewed negatively by current shareholders.
-0.50Loqtorzi revenues are projected to grow. — Steady commercial growth provides a fundamental valuation floor and reduces immediate cash burn.
+0.30Which stocks this story touches
Continue reading
6 related stories
Top 1 mover · tap to explore
Positive outlook due to upcoming clinical catalysts and revenue growth projections for Loqtorzi, balanced by capital raise risks.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
GlobeNewsWire
9h ago
